FREEHOLD, N.J., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global
developer of cell-based technologies and therapeutics, announced today the grand opening of their newly renovated Avalon Executive
Center, a three story property located at 4400 Highway 9 in Freehold, New Jersey. The property, a 64,000 square foot class A office
building, is Avalon GloboCare’s worldwide headquarters.
David Jin, M.D., Ph.D., President and CEO of Avalon GloboCare, stated, “We purchased this property a year ago
and we are thrilled with how the renovations came out. This state-of-the-art facility is a valuable asset to Avalon as it is
geographically centered making our company accessible to New York, New Jersey and Pennsylvania based healthcare providers,
hospitals, pharmaceutical firms and major university research centers. As we continue to make steady progress in the US with top
ranked hospitals, like Weill Cornell, we believe our new headquarters will serve as a hub to shape the future of cell-based
therapies and regenerative medicine.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider
dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well
as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides
strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as
competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and
specialty clinical laboratories. Through its U.S. subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc.,
Avalon will further establish our leading roles in the fields of CAR-T therapy, liquid biopsy, precision medicine and regenerative
medicine.
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking
statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include
any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes,
and results may differ materially because of more general factors including (without limitation) general industry and market
conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements
included in this press release represent the Company's views as of the date of this press release and these views could change.
However, while the Company may elect to update these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the
Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020
avco@crescendo-ir.com
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/54e556c6-bf47-4682-a516-0f8c6cc0b895
http://www.globenewswire.com/NewsRoom/AttachmentNg/63574ad0-0726-4545-addd-69f9f67e9436
http://www.globenewswire.com/NewsRoom/AttachmentNg/557ccaac-424f-4ee7-80fb-3a0b9684de25